ACHL News and Press, Achilles Therapeutics plc From 04/04/24

2024-04-04 12:31:26 ET More on Achilles Therapeutics Seeking Alpha’s Quant Rating on Achilles Therapeutics Historical earnings data for Achilles Therapeutics Financial information for Achilles Therapeutics Read the full article on Seeking Alpha ...

A look at the top 10 most actives in the United States WiSA Technologies Inc. (WISA) rose 0.8% to $0.0245 on volume of 49,663,616 shares TC BioPharm (Holdings) plc (TCBP) rose 134.2% to $3.045 on volume of 39,956,892 shares Nikola Corporation (NKLA) rose 8.1% to $0.963899 on volume of 31,...

2024-04-04 10:00:16 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli ...

2024-04-04 08:25:40 ET More on Pre-market losers & stocks. Borr Drilling: Downgrading On Potential Saudi Aramco Jackup Market Impact Borr Drilling: Fundamentals Remain Strong Ecopetrol Pays Out 18% Yield With Successful Permian Play And Gas Exploration Am...

– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host c...

– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three patients dosed in CHIRON and THETIS with...

Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...

Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...

Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...